Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain
- K. Elfhag, S. Rössner
- Psychology, Medicine
- Obesity reviews : an official journal of the…
- 1 February 2005
Successful weight maintenance is associated with more initial weight loss, reaching a self‐determined goal weight, having a physically active lifestyle, a regular meal rhythm including breakfast and healthier eating, control of over‐eating and self‐monitoring of behaviours. Expand
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors. Expand
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes. Expand
Maternal body weight development after pregnancy.
Of the factors studied here only high weight gain during pregnancy and smoking cessation can be considered as predictors for persistent weight gain after 1 year post-partum. Expand
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease. Expand
Preventive cardiologyAbstractEffects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience From the RIO-Europe…
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
- E. Näslund, B. Barkeling, +5 authors P. Hellström
- International Journal of Obesity
- 1 March 1999
It is demonstrated that GLP-1 decreases feelings of hunger and reduces energy intake in obese humans and one possible mechanism for this finding might be an increased satiety primarily mediated by gastric vagal afferent signals. Expand
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Orlistat administered for 2 years promotes weight loss and minimizes weight regain, and additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life. Expand
Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients
The addition of orlistat to lifestyle intervention was associated with maintenance of an extra 2.4 kg weight loss after VLED for up to 3 years in obese subjects and the combination oforlistat and lifestyle interventionwas associated with a reduced occurrence of type 2 diabetes. Expand
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- A. Astrup, R. Carraro, +9 authors L. V. Van Gaal
- International Journal of Obesity
- 16 August 2011
Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors. Expand